<DOC>
	<DOCNO>NCT00619112</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well temozolomide work treat patient recurrent high-grade glioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Recurrent High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy , measure 6-month progression-free survival , dose-intense temozolomide treatment schedule patient recurrent high-grade glioma . Secondary - Assess toxicity dose-intense temozolomide . - Determine overall survival patient treat dose-intense schedule . - Determine whether methylation status MGMT gene within patient ' tumor predicts great efficacy ( progression-free survival ) , patient treat protocol . - Determine whether patient ' tumor functional alteration mismatch repair ( MMR ) system PCR analysis microsatellite instability ( MSI ) whether alteration may influence outcome patient treat protocol . - Determine initial success temozolomide may influence outcome recurrent patient treat protocol evaluate patient progress two first-line adjuvant course temozolomide , patient progress within 6 month 6th adjuvant course temozolomide , patient progress 6 month temozolomide voluntarily discontinue . OUTLINE : Patients receive oral temozolomide daily day 1-7 day 15-21 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Formalin-fixed paraffin-embedded tissue block unstained paraffin slide available surgical sample evaluate molecular abnormality tumor , include ( limited ) MGMT status microsatellite instability . After completion study therapy , patient follow every 3 month survival . PROJECTED ACCRUAL : A total 40 patient WHO II grade 4 tumor ( glioblastoma multiforme [ GBM ] ) 20 patient WHO II grade 3 tumor ( non-GBM ) accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion Criteria Patients radiographically proven recurrent , intracranial malignant glioma eligible protocol . All patient must sign informed consent Patients must external beam radiation ; limit number prior chemotherapy use . Patients must &gt; 18 year old , life expectancy &gt; 8 week . Patients must Karnofsky performance status &gt; 60 . At time registration : Patients must recover toxic effect prior therapy : Patients must adequate bone marrow function . Patients must show unequivocal radiographic evidence tumor progression MRI Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : They recover effect surgery . Residual disease follow resection recurrent intracranial malignant glioma mandate eligibility study . Patients must fail prior radiation therapy must interval great equal 42 day completion radiation therapy study entry . Patients prior therapy include interstitial brachytherapy , stereotactic radiosurgery , Gliadel wafer must confirmation true progressive disease rather radiation necrosis base upon either PET MR spectroscopy surgical documentation disease . Male female patient reproductive potential must use approved contraceptive method Exclusion Criteria Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . Patients must active infection serious intercurrent medical illness . Patients must pregnant/breast feeding must agree practice adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>